Compare Abbott Laboratories (ABT) vs OneSpan Inc (OSPN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs OneSpan Inc — how do they compare? Abbott Laboratories trades at $95.58 (market cap $166.94B), while OneSpan Inc trades at $14.7 (market cap $559.43M). The key difference: Abbott Laboratories is far larger — about 298.4× OneSpan Inc's market cap, and OneSpan Inc pays the higher dividend (3.45%). Which is the better fit depends on your goals.
| ABT | OSPN | |
|---|---|---|
Market Cap | $166.94B | $559.43M |
Sector | Health | Technology |
52-Week High | $136.62 | $18.05 |
52-Week Low | $82.57 | $10.15 |
Enterprise Value | $193.69B | $517.63M |
Dividend Yield | 2.63% | 3.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
OneSpan (OSPN) trades at $15.09, up 4.5% today, showing strong momentum despite trading above the analyst consensus price target of $13.50. The stock exhibits bullish technical signals with recent earnings beats and robust profitability metrics including 28.5% net income margin and 27.8% ROE. Recent corporate developments include leadership team expansion and digital credentials launch, signaling growth initiatives.
The outlook remains positive with strong analyst support (67% buy ratings) and attractive valuation multiples (P/E 8.3x), though risks include negative cash flow trends and competitive pressures. Upside potential exists if the company maintains earnings momentum, while execution risks and market volatility present headwinds for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →
